Metformin shows promise for vascular health in adolescents with type 1 diabetes

PHILADELPHIA — Adolescents with type 1 diabetes already show early hallmarks of cardiovascular disease, and an intervention with a commonly used type 2 diabetes therapy can improve their vascular health and reduce future CV risk, according to a speaker at the Heart in Diabetes conference.

CVD is the leading cause of death in type 1 diabetes, and 35% of youths with type 1 diabetes develop at least two CV risk factors by the time they enter adulthood, Jane E.B. Reusch, MD, professor of medicine and associate director of the Center for Women’s Health Research at the University of Colorado Anschutz Medical Campus, said during a presentation. Strategies are needed, she said, to prevent or reverse the onset of CV pathology in type 1 diabetes.

“Even with all of the incredible new technology that we can apply to the management of type 1 diabetes, particularly adolescents have had worse control over the last 4 to 5 years. than they have had earlier in this decade,” said Reusch, also the former president of medicine and science for the American Diabetes Association. “If you have youth-onset type 1 diabetes, meaning before age 12 years, you have a decrease in life expectancy of 11 to 13 years according to data that just came out a few years ago.”

More over –> here

Print Friendly, PDF & Email